Changing the rules of engagement: Perspective of Zika virus by Palau Davila, Laura & Camacho Ortiz, Adrián
Medicina Universitaria. 2016;18(71):61--62
www.elsevier.es/rmuanl
EDITORIAL
Changing the  rules of engagement:  Perspective  of Zika
virus
Those  of  you  that  have  been  in the  medical  field  for
some  years  might  recall  that  over  the last  3 decades,
we  have  encountered  outbreaks  and  epidemics  caused
by  old  enemies  that  for  some reason reemerged.  These
‘‘upgraded’’  microorganisms  reappeared  because  of genetic
re-engineering  and/or  human  error;  some  examples  include
(but  are  not restricted  to)  AH1N1  influenza,  Ebola,  MERS,
measles,  cholera,  etc.  These  epidemiological  events  as  oth-
ers  cause  morbidity  in high  risk  groups  that  in most cases
include  pregnancy  and children.  But in  the last  50  years  no
infectious  agent  of  epidemic  proportions  has  been directly
linked  to  birth  defects  and  fetal  death;  Thus  the rules  of
engagement  change.
Zika  virus  (ZIKV)  is  not new,  description  of  the  virus  dates
back  to  1952,  what  is  new  is our  understanding  of  its effects
and  the  widespread  dissemination.  There  is  now  robust  evi-
dence  of  its  causal  effect  on  fetal  deaths,  microcephaly,
in utero  growth  restriction,  ventricular  calcifications,  cen-
tral  nervous  system  abnormalities,  and  changes  in  amniotic
fluid  volume  as  well  as  cerebral  and  umbilical  artery
flow.  Furthermore,  association  between  ZIKV  infection  and
Guillain--Barre  syndrome  are growing.1
The  rapid  spread  of  the virus  is  another  key factor.
Like  other  arbovirus,  ZIKV uses a  common  mosquito  (Aedes
spp.)  for  transmission  and  has  spread  exponentially  in Aedes
endemic  regions.  Since  2007, 62  countries  and  territories
have  documented  cases,  33  of those  are from  the region  of
the  Americas  since  2015.  More  than  1000  cases  of  micro-
cephaly  have  been  reported  from  8  countries  an another
13  have  reported  an  increase  incidence  in GBS  linked  to
ZIKV.2 Recent  knowledge  of  other  mechanisms  of  transmis-
sion  other  than  mosquito  bites  such as  sexual  intercourse,3
blood  donations  and  persistence  of  RNA in body  fluids4 brings
new  insight  to  the understanding  of  physiopathology.
The  disease  is  fairly  mild  in  most  cases  and  has an
extremely  low  mortality  rate  in  the immunocompetent  non-
pregnant  adult;  with  symptomatic  treatment  the  recovery
rate  is  excellent.  The  caveat  is  that  this  is  completely  differ-
ent  in  the  pregnant  patient.  Approximately  80%  of  infected
patients  will  not  develop  symptoms  and  about  40--50%  of
pregnant  woman  infected  with  ZIKV will  do so.5 To  that  the
diagnostic  capability  is  poor,  the  methods  exist  but  they  are
not  readily  available  in highly  prevalent  areas.  Detection
by  PCR  is  performed  in  reference  laboratory’s  but samples
are  mainly  drawn  from  symptomatic  patients  and  since  the
current  PCR  assay  detects  viral  RNA,  it only  will  be  positive
during  the  period  of viremia  (5--7  days),  which  may  be  rel-
atively  short  thus  underestimating  the incidence.  Antibody
testing  has  to  be  confirmed  by  elevation  of titers  or  a molec-
ular  method  and  there  is  the problem  of  cross-reactivity
between  flaviviruses.  IgM-antibody  assays  cannot  reliably
distinguish  between  ZIKV  and  dengue  virus  (DENV)  infec-
tions.  Therefore,  an  IgM-positive  result  on  an enzyme-linked
immunosorbent  assay  for  DENV  or  Zika  IgM should  be consid-
ered  indicative  of  a  recent  flavivirus  infection.  The  same
is  true  for patients  that  who  have  received  yellow  fever
or  Japanese  encephalitis  vaccine  or  have  previously  been
infected  with  another  flavivirus,  cross-reactive  antibodies
may  make it difficult  to  determine  which  flavivirus  is  caus-
ing  the  current  illness.  But  let’s  idealize  that  these  methods
are  available  and  accessible. .  .  What  do  we  tell  the pregnant
patient  after  the  test  comes  back positive?  Anything  we  can
say  other  than  ‘‘everything  will be  all  right’’  to  this  point  is
unsettling  for  a  mother  to  be,  and  unfortunately  we  cannot
assure  a good  outcome.
The  World  Health  Organization  recently  declared  ZIKV
a  global  emergency,  this  gives  the  highest  priority  for epi-
demiological  control  efforts;  among  other  things  it opens
up  grants  for  research  and  expedites  approval  of  research
protocols.  Treatment  for these  types  of viruses  such as
DENV,  Chikungunya,  etc.  are  cumbersome  to  develop  more
over  the diseases  they  cause  is self  limited.  Vector  con-
trol  measures  are  inconsistent,  especially  in underdeveloped
countries  and  are subject  to  many  environmental,  social  and
even  political  variables;  this  makes  vaccine  development
the  obvious  choice. The  technological  tools  exist  and  make  a
vaccine  feasible,  although  animal  models  and preclinical  tri-
als  will  have  to  be  expedited.  A  major  advance  in  developing
the counterattack  is that  Brazil’s  Agência  Nacional  de  Vig-
ilância  Sanitária,  the  U.S.  Food  and  Drug  Administration,  and
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the  European  Medicines  Agency  have  committed  to  prioriti-
zing  the  expedited  evaluation  of  Zika  products.  Also,  there
is  a real-time  posting  of preliminary  information  regulated
by  the  International  Committee  of  Medical  Journal  Editors
clarifying  that  prepublication  dissemination  of  critical  infor-
mation  will  not  prejudice  later  journal  publication  related
to  ZIKV  or  future  public  health  emergencies  has been  help-
ful these  advances  are unprecedented  and  will  surely  lead
to  vaccine  development.  Although  some  questions  start to
come  up,  after  the preclinical  trials  who  will  be  the first  tar-
geted  population  to  receive  the vaccine?  Nonpregnant  adult
women?  Pregnant  patients  in  high  risk  areas?  These  questions
are  going  to  have  to  be  addressed  relatively  quickly.
Every  biological  species  try  to  preserve  their  young,  par-
ents  will  literally  give  their  lives  for their  offspring  in order
to  continue  the species’  existence;  Humans  do not  differ.  We
as  a  species,  have  done  extraordinary  things  to  preserve  our
next  generations,  we  develop  vaccines,  medications,  pro-
grams  for  food  and clean water  access,  etc.  We  may  be
tolerable  to some  extent  to  other  illness,  but  not  those
that  compromise  our  unborn  children  and  their  pregnant
mothers,  here  there  is  no  tolerance.  Many  questions  remain
unanswered  for  now,  but  what  is  clear  is  that  in order  to
control  and  prevent  the  spread  of  ZIKV  we  must  change  the
way  we  commonly  think for  this old  fowl  is  not a common
one.
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